Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Journal Article (Journal Article)

Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection. Inducing the expression of latent genomes within resting CD4(+) T cells is the primary strategy to clear this reservoir. Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency in vitro, the utility of this approach has never been directly proven in a translational clinical study of HIV-infected patients. Here we isolated the circulating resting CD4(+) T cells of patients in whom viraemia was fully suppressed by antiretroviral therapy, and directly studied the effect of VOR on this latent reservoir. In each of eight patients, a single dose of VOR increased both biomarkers of cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting CD4(+) cells (mean increase, 4.8-fold). This demonstrates that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.

Full Text

Duke Authors

Cited Authors

  • Archin, NM; Liberty, AL; Kashuba, AD; Choudhary, SK; Kuruc, JD; Crooks, AM; Parker, DC; Anderson, EM; Kearney, MF; Strain, MC; Richman, DD; Hudgens, MG; Bosch, RJ; Coffin, JM; Eron, JJ; Hazuda, DJ; Margolis, DM

Published Date

  • July 25, 2012

Published In

Volume / Issue

  • 487 / 7408

Start / End Page

  • 482 - 485

PubMed ID

  • 22837004

Pubmed Central ID

  • 22837004

Electronic International Standard Serial Number (EISSN)

  • 1476-4687

Digital Object Identifier (DOI)

  • 10.1038/nature11286

Language

  • eng

Conference Location

  • England